Autophagy is a homeostatic mechanism that discards not only invading pathogens but also damaged organelles and denatured proteins via lysosomal degradation. Increasing evidence suggests a role for autophagy in inflammatory diseases, including infectious diseases, Crohn’s disease, cystic fibrosis, and pulmonary hypertension. These studies suggest that modulating autophagy could be a novel therapeutic option for inflammatory diseases. Eosinophils are a major type of inflammatory cell that aggravates airway inflammatory diseases, particularly corticosteroid-resistant inflammation. The eosinophil count is a useful tool for assessing which patients may benefit from inhaled corticosteroid therapy. Recent studies demonstrate that autophagy plays a role in eosinophilic airway inflammatory diseases by promoting airway remodeling and loss of function. Genetic variant in the autophagy gene \textit{ATG5} is associated with asthma pathogenesis, and autophagy regulates apoptotic pathways in epithelial cells in individuals with chronic obstructive pulmonary disease. Moreover, autophagy dysfunction leads to severe inflammation, especially eosinophilic inflammation, in chronic rhinosinusitis. However, the mechanism underlying autophagy-mediated regulation of eosinophilic airway inflammation remains unclear.

The aim of this review is to provide a general overview of the role of autophagy in eosinophilic airway inflammation. We also suggest that autophagy may be a new therapeutic target for airway inflammation, including that mediated by eosinophils.

\textbf{Keywords:} Autophagy; Airway inflammation; Eosinophil

Of note, this review is a good example of how autophagy can be linked to various inflammatory diseases, including eosinophilic airway inflammation. It highlights the importance of autophagy in the regulation of eosinophilic inflammation and suggests that targeting autophagy could be a novel therapeutic strategy for these diseases. The review is also well-written, providing a clear overview of the current understanding of autophagy in eosinophilic airway inflammation.
Autophagy is a dynamic process associated with the formation of autophagosomes, which are double-membrane cytoplasmic vesicles that engulf cellular components. The core proteins involved in autophagosome formation are autophagy-related genes (ATG), which comprise 4 sub-groups: 1) the ATG1/UNC-51-like kinase complex, which regulates initiation of autophagy; 2) the ubiquitin-like protein (i.e., ATG12 and ATG8/microtubule-associated protein 1 light chain 3 [LC3] conjugation system), which assists elongation of the autophagic membrane; 3) the class III PI3K/vacuolar protein sorting 34 complex I, which participates in the early stages of autophagosome formation; and 4) 2 transmembrane proteins (i.e., ATG9/mammalian Atg9 and vacuole membrane protein 1), which may contribute to the delivery process via 2 major steps: induction of autophagosomes and fusion of autophagosomes with lysosomes (9,10).

Autophagy regulates immunity by eliminating invading pathogens, regulating recognition of innate pathogens, playing roles in Ag presentation via MHC class II molecules, and controlling B- and T-cell development (11). T-cells lacking Atg5, Atg7, Atg3, or Beclin-1 showed impaired proliferation and increased cell death (12). Furthermore, autophagy dysfunction is related to various inflammatory diseases, including inflammatory bowel disease (13), asthma (14), and chronic rhinosinusitis (CRS) (15-17). For example, formation of double-membrane autophagosomes in fibroblasts from severe asthmatic patients has been observed by electron microscopy (18,19), and genetic variants of the autophagy gene Atg5 are associated with promotion of airway remodeling and loss of lung function in childhood asthma (20).

Eosinophils are a major type of inflammatory cell that play an important role in airway inflammatory diseases, including asthma (21-23). Among the many proinflammatory molecules, IL-5 is involved in eosinophil-mediated inflammation. IL-5 promotes the differentiation, survival, trafficking, activation, and effector functions of eosinophils (22). Migration of eosinophils, especially to the lungs, is regulated by chemokines such as CCL5 (regulated on activation, normal T cell expressed and secreted [RANTES]), CCL7 (MCP3), CCL11 (eotaxin 1), CCL13 (MCP-4), CCL15, CCL24, and CCL26, which bind to CCR3 (23,24). Eosinophils with inflammatory lesions in the lungs produce and release a variety of proinflammatory mediators, including basic proteins (major basic protein, eosinophil cationic protein [ECP], eosinophil peroxidase, eosinophil-derived neurotoxin), cytokines (IL-2, IL-3, IL-4, IL-5, IL-10, IL-12, IL-13, IL-16, and IL-25), chemokines (CCL5, CCL11, and CCL13), growth factors (TNF and TGF-α/β) (23,25). These proteins contribute to sustained inflammation (26) and tissue damage (23,25). For example, TGF-β produced by eosinophils in asthmatic patients is implicated in tissue remodeling through fibroblast proliferation and increased production of collagen and glycosaminoglycans (27,28).

Although evidence suggests that autophagy and eosinophils play important roles in immune responses and airway inflammation, few studies have examined the association between autophagy and eosinophils in inflammatory diseases. Here, we focus on the role of autophagy in eosinophilic airway inflammation, and suggest modulation of autophagy as a promising therapeutic approach to treat eosinophilic inflammatory diseases.

ROLE OF AUTOPHAGY IN AIRWAY INFLAMMATION DISEASES

Asthma
Asthma is a chronic airway disease characterized by airway hyperresponsiveness (AHR) and inflammation caused by molecular and cellular responses (29). Various types of inflammatory
cell are involved in the pathogenesis of asthma, including dendritic cells, mast cells, eosinophils and lymphocytes (30). Asthma is typically associated with an imbalance between Th1 and Th2 pathways; over-driven Th2-mediated inflammation leads to airway inflammation and asthma (31). In such situation, eosinophils play important roles in augmenting AHR, mucus production, and airway remodeling in allergic asthma by producing IL-13 and leukotrienes from eosinophil lipid bodies (23,32). Blood eosinophil counts correlate with the severity of allergic asthma (33), and electron microscopy reveals large numbers of eosinophils in the bronchial mucosa of patients with severe allergic asthma (32). Accordingly, the current focus of asthma treatment is the use of anti-inflammatory drugs such as inhaled corticosteroids. However, these drugs often failed to control asthma in some patients (34). Recent studies suggest that asthma pathogenesis is largely heterogeneous and complex, which is not simply driven by allergen-specific Th2 lymphocytes as expected in allergic asthma. Some patients were characterized by the upregulation of IFN-γ, IL-17, and neutrophils in their lungs, in which airway neutrophilia correlated with asthma severity (35-38). Furthermore, consistent with the role of IL-17 in neutrophil recruitment, Th17 cells promoted neutrophilic inflammation, and contributed to the development of AHR in concert with Th2 cells in asthma animal models (39). Thus, a novel therapeutic target for treating diverse types of asthma, including eosinophilic asthma, is needed. Recent studies suggest that autophagy is a promising candidate.

Poon et al. (20) showed that a single-nucleotide polymorphism (SNP) rs12212740 G>A of Atg5 correlated significantly with a reduction in pre-bronchodilator forced expiratory volume-1s (FEV1) in asthmatic patients (Table 1). They also used electron microscopy to show that fibroblasts and epithelial cells in bronchial biopsy tissue from asthmatic patients harbored more double-membrane autophagosomes than tissue from a healthy subject (20). Martin and colleagues (18) showed that SNPs of Atg5 and Atg7, and 2 SNP variants (rs12201458 and

![Table 1. Autophagy and its impact on chronic airway inflammatory diseases](https://immunenetwork.org)

| Disease | Species | Autophagy modulation | Disease phenotype affected | Autophagy role | Reference |
|---------|---------|----------------------|---------------------------|----------------|-----------|
| Asthma  | Human | SNPs of ATG5 | Reduced FEV1 | Protective | Poon et al. (20) |
| Human | SNPs of ATG5 and ATG7 | Associated with severe adult asthma | Protective | Martin et al. (18) |
| Human | Baf-A1, 3-MA | Associated with childhood asthma | Protective | Ghavami et al. (42) |
| Human | ATG7 knockdown in hATMyoD cells | Reduced fibrilotic effect of TGF-β1 | Protective | McAlinden et al. (43) |
| Human | CQ in ASM cell | Reduced airway remodeling markers including collagen-1 and phospho-SMAD2/3 | Protective | Liu et al. (40) |
| Mouse | 3-MA (intraperitoneal) | Decreased IL-5 level | Protective | Suzuki et al. (41) |
| Mouse | Atg5 knockdown (intranasal) | Decreased eosinophil count | Protective | Gavami et al. (42) |
| Mouse | CQ (intranasal) | Decreased expression of Beclin-1 and Atg5 | Protective | McAlinden et al. (43) |
| COPD | Human | Dysfunction of lung epithelium | Apoptosis activation | Protective | Chen et al. (52) |
| Human | Beclin-1 or LC3B knockdown | ROS activation | Protective | Kim et al. (53) |
| Human | Beclin-1, or LC3B knockdown | Emphysema | Protective | Chen et al. (54) |
| Human | Beclin-1, Atg5, or Atg7 knockdown | Apoptosis inactivation | Protective | Kim et al. (53) |
| Human | Beclin-1, Atg5, or Atg7 knockdown | Inhibition of autophagosome formation | Protective | Chen et al. (54) |
| CRS | Human | Reduced LC3 in NP-derived fibroblast | Increased NPs | Protective | Chen et al. (15) |
| Human | Reduction of LC3 in NP-derived fibroblasts | Increased NPs | Protective | Wang et al. (16) |
| Mouse | Myeloid cell-specific deficiency of Atg7 | Increased COX-2 expression | Protective | Choi et al. (77) |

H-PGDS, hematopoietic prostaglandin D2 synthase.
rs510432) of Atg5 are associated with childhood asthma (Table 1). These findings were tested in a murine model of asthma (Table 1) (40,41). Inhibition of autophagy by intraperitoneal injection of 3-methyladenine (3-MA) and intranasal knockdown of Atg5 led to a marked improvement in AHR, the number of infiltrating eosinophils, IL-5 levels in bronchoalveolar lavage fluid, and histological inflammatory features (40). However, Suzuki et al. (41) showed that deficiency of CD11c-specific autophagy promotes neutrophilic airway inflammation in a murine asthma model. They found that impaired autophagy induced Th17 polarization, resulting in refractory asthma (41). Although they demonstrated a role for autophagy in neutrophilic airway inflammation, but not eosinophilic inflammation, the results suggest that autophagy plays an important and diverse role in asthma.

In addition, recent studies demonstrated that autophagy plays a crucial role in airway remodeling in airway smooth muscle (ASM) cells (Table 1). Ghavami et al. (42) showed that autophagy is a regulator of fibrogenesis induced by TGF-β1 in primary human atrial myofibroblasts (hATMyofbs). TGF-β1 promoted collagen-I and fibronectin synthesis in hATMyofbs, which correlated with autophagic activation in these cells. Autophagy inhibition by ATG5 deficiency or treatment with bafilomycin-A1 (Baf-A1) and 3-MA decreased the fibrotic effect of TGF-β1 (42). McAlinden et al. (43) investigated the correlation between autophagy activation and asthma airway remodeling; human asthmatic tissues showed thickened epithelium, greater lamina propria depth, and increase in ASM bundles with higher expression of Beclin1 and ATG5 along with reduced p62 compared with non-asthmatic controls. They also showed that TGF-β1 induces upregulation of airway remodeling markers, collagen-1 and SMAD2/3 phosphorylation (pro-fibrotic signaling) along with the increased expression of Beclin-1 and LC3B-II (a marker of autophagosome formation) in ASM cells, which was reversed by an autophagy inhibitor, chloroquine (CQ). CQ also prevented accumulation of collagen in the lung of murine asthma models (43).

Furthermore, autophagy is a critical mediator of asthma exacerbations due to viral infection as well as allergic asthma (14). Viral infection is associated with exacerbation of acute asthma. Rhinovirus, severe respiratory syncytial virus, influenza viruses, coronaviruses, and adenoviruses are often detected in the airways of asthma patients (14). Treatment with Baf-A1 inhibited vacuolar-type H+-ATPase-mediated degradation of sequestered material and blocked autophagy flux by interfering with late-stage autophagosome-lysosome fusion in lung epithelial cells, resulting in growth inhibition of influenza A viruses (44). An experimental model based on mouse hepatitis virus (MHV), a prototype coronavirus used in replication and function studies, revealed that autophagy is required for viral replication, particularly for the formation of double membrane vesicle-bound MHC replication complexes (45). Further study revealed that a coronavirus non-structural protein 6 expressed by the MHV and severe acute respiratory syndrome coronavirus activates autophagy by generating autophagosomes independently of starvation (14,46). Thus, given its significant impact on asthma pathogenesis, further studies are needed to investigate the role of autophagy in the context of different cell types and to establish a therapeutic strategy for its regulation.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

COPD, a major global health epidemic, is associated with chronic inflammation of the airways and lung parenchyma (47,48). The main symptoms are shortness of breath, chronic cough, and excessive production of sputum. Chronic exposure of the airways to environmental
pollution is a main cause of COPD; indeed, approximately 15% of smokers suffer from this
disease (49). COPD differs from asthma in that the main characteristic is irreversible airflow
obstruction (49,50). The physiological abnormalities that characterize COPD are emphysema
and obliteration of small airways (50). Although emphysema can occur independently of small
airway narrowing, and vice versa, these 2 pathologies usually coexist in COPD (50). Narrowing
of the small airways is caused by inflammation, increased airway muscle mass and fibrosis in
the airway wall, and accumulation of inflammatory mucus exudates in the lumen (50).

Although the major inflammatory cells involved in COPD are CD8+ T cells, neutrophils and
macrophages, some patients have eosinophil involvement (similar to that in asthma) (47).
As mentioned before, eosinophils migrate in response to cytokines (IL-5 in particular) and
specific chemokines (such as eotaxin I and RANTES). Exacerbation of COPD is triggered
by persistent inflammation, which is itself caused by eosinophil-derived proinflammatory
mediators such as basic proteins, cytokines, and growth factors (51).

Recent studies demonstrate an association between autophagy and COPD (Table 1) (52-54).
Chen et al. (52) showed that expression of LC3B-II, ATG4, ATG5, ATG12, and ATG7
is higher in individuals with COPD than in those without, and that treatment of primary
human bronchial epithelial cells with aqueous cigarette-smoke (CS) extract induces LC3B-
II. They also demonstrated a regulatory role for LC3B during epithelial cell apoptosis in a
CS-induced lung cell injury model (52,53). Apoptosis is implicated in the pathogenesis of
COPD. Treatment of epithelial cells with CS extract initiates the extrinsic apoptosis pathway,
which involves assembly of the Fas-dependent death-inducing signaling complex (DISC) and
activation of caspase-8; it also induced expression and conversion of the autophagic regulator
LC3B, increased autophagosome formation, and increased caspase-3 activation. siRNA-
mediated knockdown of autophagic proteins Beclin-1 or LC3B in epithelial cells inhibits
assembly of the Fas-dependent DISC (52,53). Moreover, apoptotic indices and emphysema
development were reduced markedly in LC3B knock-out mice exposed to CS (54).

The mechanism by which CS induces autophagy in epithelial cells is unclear; however,
oxidative stress is a possible link that connects COPD to autophagy. Oxidative stress can
damage lipids, proteins and DNA, and also activate autophagy (55). Furthermore, it is
recognized as a major factor that predisposes an individual to developing COPD (56). Various
types of inflammatory cell including eosinophils and structural cells produce ROS in the
airways of a COPD patient (56,57). Treatment with the antioxidants such as N-acetyl-L-
cysteine reverses starvation-induced autophagosome formation (which is associated with
intracellular ROS production) in cultured cells (58). H2O2-induced autophagic cell death can
be prevented by knockdown of ATG such as Beclin-1, Atg5, and Atg7 (59). Indeed, exposure to
CS induces pro-oxidant states in several cell types, including epithelial cells (60). In addition,
chemical inhibitors of NADPH oxidase, a membrane-dependent source of ROS, inhibit CS
extract-induced activation of LC3B (54). The evidence cited above suggests that increased
activation of autophagic pathways may trigger or exacerbate COPD. Thus, resolution of
autophagy should be studied with respect to alleviating COPD.

CRS

CRS is characterized by chronic inflammation of the sinonasal mucosa. Clinical symptoms
include sinus pressure, nasal congestion, rhinorrhea, and a reduced sense of smell persisting
for more than 12 wk (61). It is commonly categorized into 2 groups based on the presence or absence of nasal polyps (NPs): chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP) (62). The 2 groups show distinct inflammatory patterns. Whereas CRSsNP is characterized by type 1 inflammation with increased levels of IFN-γ in the inflamed sinus mucosa and low ECP/myeloperoxidase ratios, CRSwNP is typically characterized by type 2 inflammation, which is associated with a typical Th2-skewed eosinophilic inflammation with high IL-5 and ECP concentrations in the polyps (63,64). IL-5 is a potent activator and survival factor for eosinophils. Several reports show that eosinophilic inflammation is dominant in patients with severe refractory CRS (65,66). However, recent findings in Eastern Asia countries showed that CRSwNP can be classified into eosinophilic and non-eosinophilic type (67). NP from Caucasian patients are mainly eosinophil-dominant with robust Th2 response (>80%), whereas NP from Asian patients (Korea, Japan, and China) are characterized by less infiltration of eosinophils but are largely neutrophil-dominant (>50%) with mixed Th1 or Th17 type inflammation (68-72). Of interest, NP from Asian patients born and resided in the United States appears non-eosinophil-dominant, suggesting the contribution of genetic factors to eosinophilic inflammation in NP (73).

Another core pathologic feature of CRS is elevated prostaglandin D2 (PGD2) levels. Upregulation of PGD2 in NPs correlates strongly with the number of mast cells that mainly produce PGD2 and play an important role in orchestrating eosinophil infiltration in patients with CRS (74-76). Also, expression of PGD2 synthase is increased in patients with CRSwNP and correlates positively with eosinophilic inflammation (77). However, it is unclear why these pathologic features occur in CRS.

Previous reports suggest that autophagy plays an important role in CRS (Table 1) (15,16). Chen et al. (15) showed that expression of LC3 protein fell markedly, but Akt/mTOR signaling (a negative regulator of autophagy) was activated, in NPs from patients with CRSwNP but not in individuals with normal nasal mucosa. In addition, they demonstrated a negative correlation between autophagy and NPs; also, formation of LC3 puncta (an alternative indicator of autophagy) decreased in NP-derived fibroblasts (15). In another report, Wang et al. (16) showed that NP tissues are deficient in autophagy and that cyclooxygenase 2 (COX-2) is negatively regulated by autophagy in NP-derived fibroblasts. LC3 and COX-2 (a common indicator of inflammation) were analyzed by immunoblotting in fresh tissues from NPs and control nasal mucosa. LC3 expression was decreased, while COX-2 expression increased significantly, in fresh NP tissues compared with control nasal mucosa (16). In addition, COX-2 expression by NP-derived fibroblasts and nasal mucosa-derived fibroblasts was reduced by starvation-induced autophagy and by overexpression of LC3; however, it increased upon inhibition of autophagy by 3-MA (16).

Choi et al. (17) used a murine model of CRS (mice in which Atg7 is conditionally deleted in a myeloid cell-specific manner) to show that disruption of autophagy in CRS is linked to dysregulation of PGD2 production and eosinophilic inflammation (Table 1). Indeed, more severe exacerbation of CRS was induced in myeloid cell-specific Atg7-deficient mice than in wild-type mice with increased infiltration of eosinophils and production of PGD2 (17). In addition, depletion of autophagy-deficient macrophages alleviated eosinophilic inflammation and PGD2 dysregulation significantly (17). These findings suggest a critical role of autophagy in exacerbating eosinophilic inflammation and in the pathologic features associated with CRS. Also, it suggests the possibility that autophagy may be a valuable therapeutic target for resolution of eosinophilic inflammation in CRS.
CONCLUSION

Undoubtedly, the role of eosinophils in airway inflammation is important. Here, we describe the importance of autophagy in asthma, COPD, and CRS, focusing on eosinophil-mediated airway inflammations.

SNP rs12212740 G>A of Atg5 correlates significantly with loss of pre-bronchodilator FEV1 in asthmatic patients. Inhibition of autophagy in a murine asthma model improves AHR, reduces the number of infiltrating eosinophils, and reduces IL-5 levels in bronchoalveolar lavage fluid. In addition, autophagy is a potential link between virus infection and asthma. However, deficiency of CD11c-specific autophagy promotes neutrophilic inflammation in a murine asthma model. These results suggest that autophagy plays different roles depending on the cell type and/or the disease model employed. Thus, further studies are necessary if autophagy is to be targeted successfully to treat asthma.

With respect to COPD, autophagy is an important regulator of epithelial cell apoptosis, which contributes to the pathogenesis of COPD. CS extract induces not only apoptosis pathway, e.g., DISC and caspase-8, but also activates LC3B, autophagosome formation and, eventually, caspase-3 in epithelial cells. These pathways are inhibited either by siRNA-mediated knockdown of Beclin-1 or LC3B, or by an inhibitor of autophagy such as 3-MA. Indeed, autophagosome formation is higher in COPD patients than in healthy controls. It is suggested that oxidative stress is a critical mediator of apoptosis in COPD. Exposure to CS induces pro-oxidant-mediated stress in epithelial cells. Chemical inhibitors of NADPH oxidase, a membrane-dependent source of ROS, inhibit CS extract-induced activation of LC3B and apoptosis. These data implicate autophagy as an important regulator of epithelial cell apoptosis and in the pathogenesis of CS-induced COPD.

Autophagy is also linked to eosinophilic inflammation in CRS. CRSwNP is associated with a typical Th2-skewed eosinophilic inflammation, with high IL-5 and ECP levels in NPs. Another core pathologic feature of CRS is increased expression of PGD2. Upregulation of PGD2 in NPs correlates strongly with the number of mast cells, which produce PGD2 and play an important role in orchestrating eosinophil infiltration in patients with CRS. Although it is not clear how these 2 factors are linked, we provide evidence that autophagy is a key mediator. Observational studies suggest that autophagy is involved in CRS. For example, expression of LC3 protein correlates negatively with NP development and expression of COX-2. In addition, increased eosinophilic inflammation and PGD2 production induce more severe CRS in myeloid cell-specific Atg7-deficient mice than in wild-type mice. These findings reveal the critical role of autophagy in exacerbating CRS.

Although autophagy plays diverse roles, either protective or detrimental, in chronic airway inflammatory (depending on the type of cell affected and the disease model used), it holds promise as a novel therapeutic target. However, the molecular mechanism underlying disease pathogenesis is not clear. In addition to its role in regulating eosinophilic or neutrophilic inflammation, autophagy has a broad effect on diverse Th responses, likely by controlling innate immune cells. Autophagy-deficient macrophages promote production of the Th1 cytokine IFN-γ during GalN/LPS-induced liver injury (78) and dextran sulfate sodium-induced colitis (79). Autophagy-deficient myeloid cells also promote Th17 responses during Mycobacterium tuberculosis infection (80), as well as Th2 responses during eosinophilic CRS (17). These results suggest that autophagy is a versatile immune modulator that will require
careful modulation to achieve therapeutic benefit. Thus, further studies are needed to
demonstrate how autophagy contributes to the pathogenesis of various airway inflammatory
diseases, and to establish an appropriate therapeutic strategy dependent of the unique
context of different diseases.

ACKNOWLEDGMENTS

This work was supported by the Intelligent Synthetic Biology Center of the Global Frontier
Project, funded by the Ministry of Education, Science, and Technology of the Republic
of Korea (2013-0073185); by grants from the National Research Foundation of Korea
(2016R1A2B4010300); and by an MRC grant (2018R1A5A2020732), funded by the Ministry of
Science and Information Technology (MSIT) of the Korean government.

REFERENCES

1. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011;469:323-335.
PUBMED | CROSSREF
2. Jing K, Lim K. Why is autophagy important in human diseases? Exp Mol Med 2012;44:69-72.
PUBMED | CROSSREF
3. Harris J, Lang T, Thomas JP, Sukkar MB, Nabar NR, Kehrl JH. Autophagy and inflammasomes. Mol
Immunol 2017;86:10-15.
PUBMED | CROSSREF
4. Fougeray S, Pallet N. Mechanisms and biological functions of autophagy in diseased and ageing kidneys.
Nat Rev Nephrol 2015;11:34-45.
PUBMED | CROSSREF
5. Pan H, Chen L, Xu Y, Han W, Lou F, Fei W, Liu S, Jing Z, Sui X. Autophagy-associated immune responses
and cancer immunotherapy. Oncotarget 2016;7:21235-21246.
PUBMED
6. Lee JA, Yue Z, Gao FB. Autophagy in neurodegenerative diseases. Brain Res 2016;1649:141-142.
PUBMED | CROSSREF
7. Lai CH, Tsai CC, Kuo WW, Ho TJ, Day CH, Pai PY, Chung LC, Huang CC, Wang HF, Liao PH, et al. Multi-
strain probiotics inhibit cardiac myopathies and autophagy to prevent heart injury in high-fat diet-fed
rats. Int J Med Sci 2016;13:277-285.
PUBMED | CROSSREF
8. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-326.
PUBMED | CROSSREF
9. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007;9:1102-1109.
PUBMED | CROSSREF
10. Qian M, Fang X, Wang X. Autophagy and inflammation. Clin Transl Med 2017;6:24.
PUBMED | CROSSREF
11. Oh JE, Lee HK. Modulation of pathogen recognition by autophagy. Front Immunol 2012;3:44.
PUBMED | CROSSREF
12. Riffelmacher T, Simon AK. Mechanistic roles of autophagy in hematopoietic differentiation. FEBS J
2017;284:1008-1020.
PUBMED | CROSSREF
13. El-Khider F, McDonald C. Links of autophagy dysfunction to inflammatory bowel disease onset. Dig Dis
2016;34:27-34.
PUBMED | CROSSREF
14. Jyothula SS, Eissa NT. Autophagy and role in asthma. Curr Opin Palm Med 2013;19:30-35.
PUBMED | CROSSREF
15. Chen JY, Hour TC, Yang SF, Chien CY, Chen HR, Tsai KL, Ko JY, Wang LF. Autophagy is deficient in nasal
polyps: implications for the pathogenesis of the disease. Int Forum Allergy Rhinol 2015;5:119-123.
PUBMED | CROSSREF
16. Wang LF, Chien CY, Yang YH, Hour TC, Yang SF, Chen HR, Tsai KL, Ko JY, Chen JY. Autophagy is deficient and inversely correlated with COX-2 expression in nasal polyps: a novel insight into the inflammation mechanism. Rhinology 2015;53:270-276.

17. Choi GE, Yoon SY, Kim JY, Kang DY, Jang YI, Kim HS. Autophagy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis. *J Allergy Clin Immunol* 2018;141:938-950.e12.

18. Martin LJ, Gupta J, Jyothula SS, Butsch Kovacic M, Biagini Myers JM, Patterson TL, Erickson MB, He H, Gibson AM, Baye TM, et al. Functional variant in the autophagy-related 5 gene promoter is associated with childhood asthma. *Pediatr* 2012;7:e33454.

19. Poon A, Eidelman D, Laprise C, Hamid Q. ATG5, autophagy and lung function in asthma. *Autophagy* 2012;8:694-695.

20. Poon AH, Chouiali F, Tse SM, Litonjua AA, Hussain SN, Baglole CJ, Eidelman DH, Olivenstein R, Martin JG, Weiss ST, et al. Genetic and histologic evidence for autophagy in asthma pathogenesis. *J Allergy Clin Immunol* 2012;129:569-571.

21. Lapa e Silva JR, Ruffié C, Lefort J, Pretolani M, Vargaftig BB. Role of eosinophilic airway inflammation in models of asthma. *Mem Inst Oswaldo Cruz* 1997;92 Suppl 2:223-226.

22. Rothenberg ME, Hogan SP. The eosinophil. *Annu Rev Immunol* 2006;24:147-174.

23. George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. *Ther Adv Chronic Dis* 2016;7:34-51.

24. Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. *Respir Res* 2001;2:150-156.

25. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME. Eosinophils: biological properties and role in health and disease. *Clin Exp Allergy* 2008;38:709-750.

26. Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. *Front Immunol* 2014;5:570.

27. Levi-Schaffer F, Garbuzenko E, Rubin A, Reich R, Pickholz D, Gillery P, Emonard H, Nagler A, Maquart FA. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). *Proc Natl Acad Sci U S A* 1999;96:9660-9665.

28. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. *Immunol Cell Biol* 2007;85:348-356.

29. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. *Mutat Res* 2010;690:24-39.

30. Umetsu DT, DeKruyff RH. The regulation of allergy and asthma. *Immunol Rev* 2006;212:238-255.

31. KleinJan A. Airway inflammation in asthma: key players beyond the Th2 pathway. *Curr Opin Palm Med* 2016;22:46-52.

32. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. *Immunol Today* 1992;13:501-507.

33. Kay AB. The role of eosinophils in the pathogenesis of asthma. *Trends Mol Med* 2005;11:148-152.

34. Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, Plaza V; MAGIC Study Group. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire. *Respir Res* 2012;13:50.

35. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. *Allergy* 2011;66:989-998.
36. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol 2010;72:495-516.

37. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.

38. Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, Segal M, Fahy JV. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001;108:753-758.

39. Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 2009;180:720-730.

40. Liu JN, Suh DH, Trinh HK, Chwae YJ, Park HS, Shin YS. The role of autophagy in allergic inflammation: a new target for severe asthma. Exp Mol Med 2016;48:e243.

41. Suzuki Y, Maazi H, Sankaranarayanan I, Lam J, Khoo B, Soroosh P, Barbers RG, James Ou JH, Jung JU, Akbari O, et al. Lack of autophagy induces steroid-resistant airway inflammation. J Allergy Clin Immunol 2016;137:1382-1389.e9.

42. Ghavami S, Cunnington RH, Gupta S, Yeganeh B, Filomeno KL, Freed DH, Chen S, Klonisch T, Halayko AJ, Ambrose E, et al. Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts. Cell Death Dis 2015;6:e1696.

43. McAlinden KD, Deshpande DA, Ghavami S, Xenaki D, Sohal SS, Oliver BG, Haghi M, Sharma P. Autophagy activation in asthma airways remodeling. Am J Respir Cell Mol Biol 2018. doi: 10.1165/rcmb.2018-0169OC.

44. Yeganeh B, Ghavami S, Kroeker AI, Mahood TH, Stelmacl GL, Klonisch T, Coombs KM, Halayko AI. Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1. Am J Physiol Lung Cell Mol Physiol 2015;308:L270-L286.

45. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR. Coronavirus replication complex formation utilizes components of cellular autophagy. J Biol Chem 2002;279:10136-10141.

46. Cottam EM, Maier HJ, Manifava M, Vaux LC, Chandra-Schoenfelder P, Gerner W, Britton P, Kitstakis NT, Wileman T. Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate. Autophagy 2011;7:1335-1347.

47. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138:16-27.

48. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 2017;389:1931-1940.

49. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49:1700214.

50. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.

51. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2018;13:335-349.
54. Chen ZH, Lam HC, Jin Y, Kim HP, Cao J, Lee SJ, Ifedigbo E, Parameswaran H, Ryter SW, Choi AM. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. *Proc Natl Acad Sci U S A* 2010;107:18880-18885.

55. Kiffin R, Randyopadhyay U, Cuervo AM. Oxidative stress and autophagy. *Antioxid Redox Signal* 2006;8:152-162.

56. Kirkham PA, Barnes PJ. Oxidative stress in COPD. *Chest* 2013;144:266-273.

57. Ryter SW, Lee SJ, Choi AM. Autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. *Expert Rev Respir Med* 2010;4:573-584.

58. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J* 2007;26:1749-1760.

59. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. *Cell Death Differ* 2008;15:171-182.

60. Gamble E, Grootendorst DC, Hattotuwa K, O'Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegel C, Morell F, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. *Eur Respir J* 2007;30:467-471.

61. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *RhinoLOGY* 2012;50:1-12.

62. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. *J Allergy Clin Immunol* 2015;136:1442-1453.

63. Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic rhinosinusitis: inflammation. *J Allergy Clin Immunol* 2011;128:728-732.

64. Kato A. Immunopathology of chronic rhinosinusitis. *Allergol Int* 2015;64:121-130.

65. López-Chacón M, Mullol J, Pujols L. Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis. *Curr Allergy Asthma Rep* 2015;15:19.

66. Shah SA, Ishinaga H, Takeuchi K. Pathogenesis of eosinophilic chronic rhinosinusitis. *J Inflamm (Lond)* 2016;13:11.

67. Cho SW, Kim DW, Kim JW, Lee CH, Rhee CS. Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population. *Asia Pac Allergy* 2017;7:121-130.

68. Van Zele T, Claes S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, Bachert C. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. *Allergy* 2006;61:1280-1289.

69. Zhang N, Van Zele T, Perez-Novco C, Van Bruaene N, Holtappels G, DeRuyck N, Van Cauwenberge P, Bachert C. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. *J Allergy Clin Immunol* 2008;122:961-968.

70. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, Wang DY, Desrosiers M, Liu Z. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. *J Allergy Clin Immunol* 2009;124:478-484, 484.e1-484.e2.

71. Kim JW, Hong SL, Kim YK, Lee CH, Min YG, Rhee CS. Histological and immunological features of non-eosinophilic nasal polyps. *Otolaryngol Head Neck Surg* 2007;137:925-930.

72. Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, Saitoh T, Murata J. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. *Laryngoscope* 2013;123:E1-E9.
73. Mahdavinia M, Suh LA, Carter RG, Stevens WW, Norton JE, Kato A, Tan BK, Kern RC, Conley DB, Chandra R, et al. Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia. *J Allergy Clin Immunol* 2015;135:576-579.

74. Di Lorenzo G, Drago A, Esposito Pellitteri M, Candore G, Colombo A, Gervasi F, Pacor ML, Purello D’Ambrosio F, Caruso C. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. *Int Arch Allergy Immunol* 2001;125:164-175.

75. Pawankar R, Lee KH, Nonaka M, Takizawa R. Role of mast cells and basophils in chronic rhinosinusitis. *Clin Allergy Immunol* 2007;20:93-101.

76. Yoshimura T, Yoshikawa M, Otori N, Haruna S, Moriyama H. Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. *Allergol Int* 2008;57:429-436.

77. Okano M, Fujiwara T, Yamamoto M, Sugata Y, Matsumoto R, Fukushima K, Yoshino T, Shimizu K, Eguchi N, Kiniwa M, et al. Role of prostaglandin D2 and E2 terminal synthases in chronic rhinosinusitis. *Clin Exp Allergy* 2006;36:1028-1038.

78. Ilyas G, Zhao E, Liu K, Lin Y, Tesfa L, Tanaka KE, Czaja MJ. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1β. *J Hepatol* 2016;64:118-127.

79. Lee HY, Kim J, Quan W, Lee JC, Kim MS, Kim SH, Bae JW, Hur KY, Lee MS. Autophagy deficiency in myeloid cells increases susceptibility to obesity-induced diabetes and experimental colitis. *Autophagy* 2016;12:1390-1403.

80. Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delgado-Vargas M, Timmins GS, Bhattacharya D, Yang H, et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. *Proc Natl Acad Sci U S A* 2012;109:E3168-E3176.